title: Use of medication for challenging behaviour in people with intellectual disability.
authors.affiliation: Gyles Glover, MSc, MD, FRCPsych, FPPH, Co-Director, Learning Disabilities Team, Public Health England; Sarah Bernard, MD, FRCPsych, DRCOG, Child and Adolescent Learning Disability Service, South London and Maudsley NHS Foundation Trust; David Branford, PhD, FRPharmS, FCMHP, Chairman, English Pharmacy Board, Royal Pharmaceutical Society; Anthony Holland, MPhil, MRCP, FRCPsych, Diploma in Clinical Genetics, Health Foundation Chair in Learning Disabilities, Academic Department of Psychiatry, University of Cambridge; Andre Strydom, MSc, PhD, MRCPsych, Reader in Intellectual Disabilities, Mental Health Sciences Unit, University College London, UK.
authors.forename: Gyles
authors.initials: G
authors.lastname: Glover
authors.affiliation: Gyles Glover, MSc, MD, FRCPsych, FPPH, Co-Director, Learning Disabilities Team, Public Health England; Sarah Bernard, MD, FRCPsych, DRCOG, Child and Adolescent Learning Disability Service, South London and Maudsley NHS Foundation Trust; David Branford, PhD, FRPharmS, FCMHP, Chairman, English Pharmacy Board, Royal Pharmaceutical Society; Anthony Holland, MPhil, MRCP, FRCPsych, Diploma in Clinical Genetics, Health Foundation Chair in Learning Disabilities, Academic Department of Psychiatry, University of Cambridge; Andre Strydom, MSc, PhD, MRCPsych, Reader in Intellectual Disabilities, Mental Health Sciences Unit, University College London, UK.
authors.forename: Sarah
authors.initials: S
authors.lastname: Bernard
authors.affiliation: Gyles Glover, MSc, MD, FRCPsych, FPPH, Co-Director, Learning Disabilities Team, Public Health England; Sarah Bernard, MD, FRCPsych, DRCOG, Child and Adolescent Learning Disability Service, South London and Maudsley NHS Foundation Trust; David Branford, PhD, FRPharmS, FCMHP, Chairman, English Pharmacy Board, Royal Pharmaceutical Society; Anthony Holland, MPhil, MRCP, FRCPsych, Diploma in Clinical Genetics, Health Foundation Chair in Learning Disabilities, Academic Department of Psychiatry, University of Cambridge; Andre Strydom, MSc, PhD, MRCPsych, Reader in Intellectual Disabilities, Mental Health Sciences Unit, University College London, UK.
authors.forename: David
authors.initials: D
authors.lastname: Branford
authors.affiliation: Gyles Glover, MSc, MD, FRCPsych, FPPH, Co-Director, Learning Disabilities Team, Public Health England; Sarah Bernard, MD, FRCPsych, DRCOG, Child and Adolescent Learning Disability Service, South London and Maudsley NHS Foundation Trust; David Branford, PhD, FRPharmS, FCMHP, Chairman, English Pharmacy Board, Royal Pharmaceutical Society; Anthony Holland, MPhil, MRCP, FRCPsych, Diploma in Clinical Genetics, Health Foundation Chair in Learning Disabilities, Academic Department of Psychiatry, University of Cambridge; Andre Strydom, MSc, PhD, MRCPsych, Reader in Intellectual Disabilities, Mental Health Sciences Unit, University College London, UK.
authors.forename: Anthony
authors.initials: A
authors.lastname: Holland
authors.affiliation: Gyles Glover, MSc, MD, FRCPsych, FPPH, Co-Director, Learning Disabilities Team, Public Health England; Sarah Bernard, MD, FRCPsych, DRCOG, Child and Adolescent Learning Disability Service, South London and Maudsley NHS Foundation Trust; David Branford, PhD, FRPharmS, FCMHP, Chairman, English Pharmacy Board, Royal Pharmaceutical Society; Anthony Holland, MPhil, MRCP, FRCPsych, Diploma in Clinical Genetics, Health Foundation Chair in Learning Disabilities, Academic Department of Psychiatry, University of Cambridge; Andre Strydom, MSc, PhD, MRCPsych, Reader in Intellectual Disabilities, Mental Health Sciences Unit, University College London, UK.
authors.forename: Andre
authors.initials: A
authors.lastname: Strydom
mesh_terms: D014150:Antipsychotic Agents; D006801:Humans; D008607:Intellectual Disability / Q000523:psychology*; D056687:Off-Label Use
chemical_list: D014150:Antipsychotic Agents